



ProLynx Enters Funded Evaluation Agreement with GlaxoSmithKline Research & Development Limited (GSK)

SAN FRANCISCO, CA - ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs today announced the signing of a multi-project, multi-year, funded evaluation arrangement with GSK.

Under the arrangement, ProLynx will apply its hydrogel and linker technologies to undisclosed GSK proteins seeking to extend their half-lives for pre-determined periods. “This arrangement is important in validating our technology,” said Dr. Daniel Santi, Founder & President of ProLynx LLC. “We are enthusiastic about this program not just because of the value it brings to ProLynx, but also because we have the opportunity to work with the Biopharm Innovation group at GSK, an R&D unit dedicated to turning biopharm technologies into platforms for drug discovery and development,” continued Santi. Financial and technical goals of the arrangement were not disclosed.

About ProLynx LLC

ProLynx LLC is a privately held biotechnology company developing proprietary drug delivery systems (DDS) for half-life extension of proteins, peptides and small molecules. The company is seeking to apply its DDS to extend half-lives of drugs and drug candidates of pharmaceutical and biotechnology companies. ProLynx is also seeking to out-license the long lasting drug conjugates in its pre-clinical product portfolio. The company is located in San Francisco, CA. Further information about the company and its capabilities may be found online at <http://www.prolynxllc.com>.

Contact:

Peg Horn

415-552-5306

peg@prolynxllc.com

###